Journal: Cell Communication and Signaling : CCS

Article Title: JC124 confers multimodal neuroprotection in epilepsy by suppressing NLRP3 inflammasome activation: evidence from animal and human neuronal models

doi: 10.1186/s12964-025-02239-3

Figure Lengend Snippet: JC124 treatment suppresses seizures in KA-induced epileptic mice. A Study design timeline. B Structure of JC124. C Latency to the first convulsive SRS and ( D ) the number of convulsive SRSs ( n = 10). E Representative images of LFP recordings in the post-SE + vehicle, post-SE + JC124, and post-SE + VPA groups. F The number of SLEs, ( G ) the mean duration of SLE, and ( H ) the cumulative duration of SLEs in the hippocampal LFP ( n = 8). KA-induced epileptic mice treated with JC124 exhibited a marked increase in latency to the first convulsive SRS, accompanied by a reduction in the number of convulsive SRSs, as well as a decrease in the number and cumulative duration of SLEs. Data are represented as mean ± S.E.M. *** p < 0.001. ns indicates no statistical significance

Article Snippet: In accordance with previous studies [ , ] and our preliminary experiments, JC124 (CSNpharm, IL, USA; 50 mg/kg, intraperitoneally) or VPA (TargetMol, MA, USA; 200 mg/kg, intraperitoneally) was administered once daily for 28 days.

Techniques:

Journal: Drug Design, Development and Therapy

Article Title: Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid

doi: 10.2147/DDDT.S89464

Figure Lengend Snippet: Mean plasma VPA concentration–time profiles with and without AMC in healthy subjects. Note: Error bars represent standard deviation. Abbreviations: h, hour; VPA, valproic acid; AMC, amoxicillin/clavulanic acid.

Article Snippet: On day 1, subjects received a single dose of VPA 500 mg (Depakote ® ; Abbott Laboratories) with 240 mL of water.

Techniques: Clinical Proteomics, Concentration Assay, Standard Deviation